Polyclonal Antibody to Interleukin 22 Receptor (IL22R)
| Code | Size | Price |
|---|
| PAE766Hu01-20ul | 20ul | £87.00 |
Quantity:
| PAE766Hu01-100ul | 100ul | £162.00 |
Quantity:
| PAE766Hu01-200ul | 200ul | £218.00 |
Quantity:
| PAE766Hu01-1ml | 1ml | £499.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Host Type: Rabbit
Antibody Clonality: Polyclonal
Regulatory Status: RUO
Target Species: Human
Applications:
- Enzyme-Linked Immunosorbent Assay (ELISA)
- Immunocytochemistry (ICC)
- Immunohistochemistry- Frozen Section (IHC-F)
- Immunohistochemistry- Paraffin Embedded (IHC-P)
- Western Blot (WB)
Documents
Further Information
Alternative Names:
IL22RA1; CRF2-9; ZcytoR11; Interleukin 22 Receptor,Alpha 1; Cytokine receptor class-II member 9
Buffer Formulation:
0.01M PBS, pH7.4, containing 0.01% Proclin-300, 50% glycerol.
Item Name:
Interleukin 22 Receptor
Reactivity:
Mu;Ra;Po;
Source:
Polyclonal antibody preparation
Usage:
Western blotting: 1-5ug/mL<br/>Immunocytochemistry in formalin fixed cells: 5-20ug/mL<br/>Immunohistochemistry in formalin fixed frozen section: 5-20ug/mL<br/>Immunohistochemistry in paraffin section: 5-20ug/mL<br/>Enzyme-linked Immunosorbent Assay: 0.05-2ug/mL<br/>Optimal working dilutions must be determined by end user.
Related Products
| Product Name | Product Code | Supplier | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Immunogen | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Recombinant Interleukin 22 Receptor (IL22R) | RPE766Hu01 | Cloud-Clone Corp. | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||